Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582081 | 0.79 | — | — | |
| SCHEMBL11499843 | 0.74 | ACHE (0.34) | — | |
| SCHEMBL27652109 | 0.74 | CYP2B6 (0.34) | CA1CA9CA12CA2CYP2B6 | |
| SCHEMBL31020837 | 0.72 | CA1 (0.34) | CA1CA9CA12CA2CYP2B6 | |
| SCHEMBL160028 | 0.72 | CA1 (0.34) | CA1CA9CA12CA2CYP2B6 | |
| SCHEMBL1595435 | 0.72 | CA12 (0.38) | CA1CA9CA12CA2LTA4H | |
| SCHEMBL9208 | 0.70 | CYP2B6 (0.43) | CA1CA9CYP2B6 | |
| SCHEMBL29364609 | 0.70 | CYP2B6 (0.43) | CA1CA9CYP2B6 | |
| SCHEMBL2281562 | 0.70 | CYP2B6 (0.43) | CA1CA9CYP2B6 | |
| SCHEMBL2289180 | 0.70 | CYP2B6 (0.43) | CA1CA9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340562-A1 | CHROMANE IMAGING LIGANDS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| US-20230203214-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-06-29 | — | — | US | disclosed |
| EP-4153598-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-03-29 | — | — | EP | disclosed |
| WO-2023278729-A1 | CHROMANE IMAGING LIGANDS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-05 | — | — | WO | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2021233800-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2021-11-25 | — | — | WO | disclosed |
| EP-3519416-B1 | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS MGLUR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2021-03-31 | — | — | EP | disclosed |
| CN-103848839-A | Synthesis method of pyran[2,3-b]pyridine derivatives | UNIV JIANGSU NORMAL | 2014-06-11 | — | — | CN | disclosed |
| CN-103848839-A | Synthesis method of pyran[2,3-b]pyridine derivatives | UNIV JIANGSU NORMAL | 2014-06-11 | — | — | CN | disclosed |
| EP-0178633-B1 | 2-phenylpyrano[2,3-b]pyridines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-01-08 | — | — | EP | disclosed |
| US-5019571-A | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1991-05-28 | — | — | US | disclosed |
| US-5011938-A | Antimicrobials | ELI LILLY AND COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| US-4902707-A | Bicyclic pyrazolidinones, compositions and use | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
| EP-0327239-A1 | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1989-08-09 | — | — | EP | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| US-4588733-A | 2-phenylpyrano[2,3-b]pyridines and their use in inhibiting viruses | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0178633-A2 | 2-phenylpyrano[2,3-b]pyridines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | CA1 4353/4885CA9 4603/4885CA12 4845/4885 |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CA1 1259/4885CA9 2311/4885CA12 1183/4885 |
| US-20250340562-A1 | CHROMANE IMAGING LIGANDS | GRM2, GRM1, GRIA2 | CA1 1221/4885CA9 3913/4885CA12 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.